These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
430 related articles for article (PubMed ID: 31325141)
21. Reappraisal of Contemporary Pharmacokinetic and Pharmacodynamic Principles for Informing Aminoglycoside Dosing. Bland CM; Pai MP; Lodise TP Pharmacotherapy; 2018 Dec; 38(12):1229-1238. PubMed ID: 30403305 [TBL] [Abstract][Full Text] [Related]
22. Optimizing Antibiotic Dosing Strategies for the Treatment of Gram-negative Infections in the Era of Resistance. Monogue ML; Kuti JL; Nicolau DP Expert Rev Clin Pharmacol; 2016; 9(3):459-76. PubMed ID: 26678036 [TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetic/pharmacodynamic adequacy of polymyxin B against extensively drug-resistant Gram-negative bacteria in critically ill, general ward and cystic fibrosis patient populations. Xie J; Roberts JA; Lipman J; Cai Y; Wang H; Zhao N; Xu X; Yang S; Li Y; Zhang K Int J Antimicrob Agents; 2020 Jun; 55(6):105943. PubMed ID: 32184115 [TBL] [Abstract][Full Text] [Related]
24. Prolonged Versus Intermittent Infusion of β-Lactam Antibiotics: A Systematic Review and Meta-Regression of Bacterial Killing in Preclinical Infection Models. Dhaese S; Heffernan A; Liu D; Abdul-Aziz MH; Stove V; Tam VH; Lipman J; Roberts JA; De Waele JJ Clin Pharmacokinet; 2020 Oct; 59(10):1237-1250. PubMed ID: 32710435 [TBL] [Abstract][Full Text] [Related]
25. Shape does matter: short high-concentration exposure minimizes resistance emergence for fluoroquinolones in Pseudomonas aeruginosa. Rees VE; Bulitta JB; Nation RL; Tsuji BT; Sörgel F; Landersdorfer CB J Antimicrob Chemother; 2015 Mar; 70(3):818-26. PubMed ID: 25381167 [TBL] [Abstract][Full Text] [Related]
26. Association between the rate of fluoroquinolones-resistant gram-negative bacteria and antibiotic consumption from China based on 145 tertiary hospitals data in 2014. Yang P; Chen Y; Jiang S; Shen P; Lu X; Xiao Y BMC Infect Dis; 2020 Apr; 20(1):269. PubMed ID: 32264851 [TBL] [Abstract][Full Text] [Related]
27. Elucidation of the pharmacokinetic/pharmacodynamic determinants of fosfomycin activity against Pseudomonas aeruginosa using a dynamic in vitro model. Bilal H; Peleg AY; McIntosh MP; Styles IK; Hirsch EB; Landersdorfer CB; Bergen PJ J Antimicrob Chemother; 2018 Jun; 73(6):1570-1578. PubMed ID: 29506207 [TBL] [Abstract][Full Text] [Related]
28. Antibacterial and antibiotic-resistance modifying activity of the extracts and compounds from Nauclea pobeguinii against Gram-negative multi-drug resistant phenotypes. Seukep JA; Sandjo LP; Ngadjui BT; Kuete V BMC Complement Altern Med; 2016 Jul; 16():193. PubMed ID: 27386848 [TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics, pharmacodynamics and therapeutics of pradofloxacin in the dog and cat. Lees P J Vet Pharmacol Ther; 2013 Jun; 36(3):209-21. PubMed ID: 23406008 [TBL] [Abstract][Full Text] [Related]
30. Comparing the minimum inhibitory and mutant prevention concentrations of selected antibiotics against animal isolates of Pasteurella multocida and Salmonella typhimurium. Wentzel JM; Biggs LJ; Van Vuuren M Onderstepoort J Vet Res; 2022 Jan; 89(1):e1-e7. PubMed ID: 35144445 [TBL] [Abstract][Full Text] [Related]
31. How predictive is PK/PD for antibacterial agents? Frimodt-Møller N Int J Antimicrob Agents; 2002 Apr; 19(4):333-9. PubMed ID: 11978504 [TBL] [Abstract][Full Text] [Related]
32. Mutant prevention concentration-based pharmacokinetic/pharmacodynamic indices as dosing targets for suppressing the enrichment of levofloxacin-resistant subpopulations of Staphylococcus aureus. Liang B; Bai N; Cai Y; Wang R; Drlica K; Zhao X Antimicrob Agents Chemother; 2011 May; 55(5):2409-12. PubMed ID: 21343454 [TBL] [Abstract][Full Text] [Related]
33. Emergence of Global Antibiotic Resistance. Morehead MS; Scarbrough C Prim Care; 2018 Sep; 45(3):467-484. PubMed ID: 30115335 [TBL] [Abstract][Full Text] [Related]
34. In vitro activity of XF-73, a novel antibacterial agent, against antibiotic-sensitive and -resistant Gram-positive and Gram-negative bacterial species. Farrell DJ; Robbins M; Rhys-Williams W; Love WG Int J Antimicrob Agents; 2010 Jun; 35(6):531-6. PubMed ID: 20346634 [TBL] [Abstract][Full Text] [Related]
35. Assessing the pharmacodynamic profile of intravenous antibiotics against prevalent Gram-negative organisms collected in Colombia. Villegas MV; Briceno DF; Ruiz SJ; Furtado GH; Nicolau DP Braz J Infect Dis; 2011; 15(5):413-9. PubMed ID: 22230846 [TBL] [Abstract][Full Text] [Related]